Jackson Creek Investment Advisors LLC Invests $1.31 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Jackson Creek Investment Advisors LLC bought a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 103,592 shares of the company’s stock, valued at approximately $1,313,000.

Several other hedge funds have also added to or reduced their stakes in DAWN. R Squared Ltd bought a new stake in Day One Biopharmaceuticals in the 4th quarter valued at about $31,000. Quest Partners LLC boosted its stake in shares of Day One Biopharmaceuticals by 9,238.6% in the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after buying an additional 7,668 shares during the period. E Fund Management Co. Ltd. bought a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $143,000. Dynamic Technology Lab Private Ltd acquired a new stake in Day One Biopharmaceuticals during the third quarter worth approximately $174,000. Finally, XTX Topco Ltd bought a new position in Day One Biopharmaceuticals during the 3rd quarter worth $178,000. 87.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. The Goldman Sachs Group cut their target price on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Bank of America reduced their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. JPMorgan Chase & Co. decreased their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Finally, Wedbush reissued an “outperform” rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $34.57.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at $1,531,059.40. The trade was a 8.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Charles N. York II sold 4,370 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the transaction, the chief financial officer now owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. This trade represents a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,064 shares of company stock valued at $651,225 in the last 90 days. Corporate insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Trading Down 4.7 %

Shares of Day One Biopharmaceuticals stock opened at $8.67 on Friday. The firm has a market capitalization of $878.75 million, a PE ratio of -8.42 and a beta of -1.38. The firm’s 50 day moving average is $11.85 and its 200 day moving average is $13.24. Day One Biopharmaceuticals, Inc. has a 1 year low of $8.02 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million. As a group, research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.